Sclavo Vaccine Association (SVA)

Sclavo Vaccines Association (SVA) (http://www.sclavo.org) is a non-profit association whose main objective is scientific research targeted towards the discovery and study of advanced immunisation technologies with the aim of contributing to the innovative development of safe, effective prophylactic and therapeutic vaccines. SVA has 11 member institutions from seven European countries includeing: Academisch Ziekenhuis Leiden (NL), Fondazione Humanitas per la Ricerca (IT), Institute for Research in Biomedicine (CH), Novartis Vaccines Institute for Global Health (IT), St. George’s, University of London (UK), Statens Serum Institut (DK), University of Geneva (CH), University of Gothenburg (SE), University of Siena (IT), Surrey University (UK).

Role in the TRANSVAC project

Main staff involved in TRANSVAC

Rino Rappuoli, President SVA; Donata Medaglini Vice-President SVA;

The Facility

TNA or Training provided

Description

 

 

 

Description

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.

Be the first to know about the upcoming application calls, follow European Vaccine Initiative on:

  • LinkedIn Social Icon
  • Twitter Social Icon
Subscribe to TRANSVAC´s Mailing list

© 2020 European Vaccine Initiative. Designed by European Vaccine Initiative